|
|
 |
|
Viewing report
|
|
|
|
Neurological Disease: Early-Stage R&D and Dealmaking
Decision Resources, Inc., Aug 2009, Pages: 25
How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable to overcome, as witnessed by the failures of agents initially deemed highly promising. However, careful planning—including risk mitigation through strategic collaboration—can allow a drug developer to take advantage of the significant opportunity in this market.
Questions Answered in This Report
Although therapies are available for neurological disorders, most of these conditions remain under treated, and no cures are available.
- What benefits do novel therapies have over existing treatment options?
- How can companies mitigate the risk associated with drug development?
Much of the innovation in drug discovery and design occurs in small companies.
- What companies are developing novel approaches to treat neurological diseases?
- What collaborations have they forged with Big Pharma?
The neurology market is entering a period of stagnation.
- What is currently driving market growth?
- What are the greatest needs in the treatment of neurological diseases?
Scope
- Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein, NMDA, nicotinic acetylcholinesterase receptor, HMG-CoA reductase.
- Novel technologies for neurology: Deep-brain stimulation, stem cell therapy.
- Focus on diseases with neuronal degradation as a primary symptom: Alzheimer’s disease (AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson’s disease (PD), Huntington’s disease (HD), ALS and other motor neuron diseases.
Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
- Outlook: Challenges in drug development, recent deal making, need for increased research, benefits of academic collaborations.
Customers who bought this item also bought
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease
Alzheimer Disease - New Drugs, Markets and Companies
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Emerging Drug Targets in Alzheimer's Disease
Advances in Alzheimer’s Disease Drug Discovery
Thought Leader Insight & Analysis Report: Alzheimer’s Disease Q2 2010
The Neurotechnology Industry 2011 Report
The Central Nervous Systems Market 2010 Report
Pain Therapeutics - Drugs, Markets and Companies
Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011
|
|
|
|
